NYSE:PKI - PerkinElmer Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$85.63 +1.13 (+1.34 %)
(As of 08/15/2018 04:59 AM ET)
Previous Close$84.50
Today's Range$84.54 - $85.76
52-Week Range$63.11 - $87.72
Volume623,200 shs
Average Volume646,332 shs
Market Capitalization$9.40 billion
P/E Ratio29.53
Dividend Yield0.33%
Beta0.88
PerkinElmer logoPerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNYSE:PKI
CUSIP71404610
Phone781-663-6900

Debt

Debt-to-Equity Ratio0.79
Current Ratio1.69
Quick Ratio1.17

Price-To-Earnings

Trailing P/E Ratio29.53
Forward P/E Ratio23.40
P/E Growth1.88

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales4.20
Cash Flow$3.9570 per share
Price / Cash21.64
Book Value$22.71 per share
Price / Book3.77

Profitability

EPS (Most Recent Fiscal Year)$2.90
Net Income$292.63 million
Net Margins5.51%
Return on Equity14.25%
Return on Assets6.29%

Miscellaneous

Employees11,000
Outstanding Shares110,730,000
Market Cap$9.40 billion

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Monday, July 23rd. Investors of record on Friday, October 19th will be given a dividend of $0.07 per share on Friday, November 9th. This represents a $0.28 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Thursday, October 18th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) announced its quarterly earnings data on Wednesday, August, 1st. The medical research company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.86 by $0.05. The medical research company had revenue of $703.55 million for the quarter, compared to analysts' expectations of $694.70 million. PerkinElmer had a net margin of 5.51% and a return on equity of 14.25%. PerkinElmer's quarterly revenue was up 28.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share (EPS) guidance of approx $3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.61.

What price target have analysts set for PKI?

11 Wall Street analysts have issued 12 month target prices for PerkinElmer's shares. Their forecasts range from $67.00 to $95.00. On average, they anticipate PerkinElmer's stock price to reach $80.1236 in the next twelve months. This suggests that the stock has a possible downside of 6.4%. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)
  • Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)
  • Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)
  • Mr. Frank A. Wilson, Advisor (Age 59)

Has PerkinElmer been receiving favorable news coverage?

News coverage about PKI stock has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PerkinElmer earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media stories about the medical research company an impact score of 48.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for PerkinElmer.

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.75%), BlackRock Inc. (5.47%), Massachusetts Financial Services Co. MA (2.95%), King Luther Capital Management Corp (2.27%), Bank of New York Mellon Corp (0.74%) and Dimensional Fund Advisors LP (0.69%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, Joel S Goldberg, Kenton J Sicchitano, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Acadian Asset Management LLC, Sensato Investors LLC, BlackRock Inc., Bank of New York Mellon Corp, Employees Retirement System of Texas, Systematic Financial Management LP and FMR LLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., Tredje AP fonden, Schwab Charles Investment Management Inc., Chilton Investment Co. LLC, Tributary Capital Management LLC and Cumberland Partners Ltd. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $85.63.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $9.40 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $2.90 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  750
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.